Sheraton Grand Phoenix
Phoenix Ballroom DE (Third Level)
340 North 3rd Street
Phoenix, AZ 85004
5:30 PM–6:00 PM: Registration and Dinner
6:00 PM–6:15 PM: Welcome, Introduction, and Polling
6:15 PM–6:45 PM: Interdisciplinary Collaboration for Improving Gaucher Disease Recognition and Diagnosis
6:45 PM–7:15 PM: Personalizing the Evaluation, Management, and Monitoring of Patients With Gaucher Disease Type 1
7:15 PM–7:30 PM: Take-Home Strategies, Ask an Expert Q&A, and Conclusions
Awareness of diagnostic criteria and treatment options for Gaucher disease type 1 is imperative to prevent misdiagnosis and failure to institute appropriate treatment measures. Although patients with Gaucher disease type 1 are most frequently referred to hematologists because the most common presentation of the disease is splenomegaly with cytopenia, only 20% of hematologists consider Gaucher disease in the differential diagnosis of such patients. With the recent publication of diagnostic algorithms for adult and pediatric patients with this disease, hematologists and medical geneticists must work together to ensure the accurate and timely recognition of patients with this disease to ensure optimal treatment. However, the variable pattern and severity of this disease and the uncertain manner of progression over the long term render the decision to initiate enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) in treatment-naïve patients or switch from ERT to SRT in treatment-experienced patients with Gaucher disease type 1 a hurdle for many clinicians.
In this activity, experts in the recognition and management of Gaucher disease type 1 consider the key tenets for improving interdisciplinary collaboration in the diagnosis of this disease, provide guidance in personalizing the management of Gaucher disease type 1, and offer strategies for monitoring individuals with this disease over the long term.
Upon completion of this activity, participants should be better able to:
This activity has been designed to meet the educational needs of medical geneticists, genetic counselors, hematologists, hematologist-oncologists, and other clinicians involved in the management of patients with Gaucher disease type 1.
In order to receive credit, participants must attend the live activity and complete the request for credit. There are no prerequisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon completion of the request for credit at the end of the post-test.
Release and Expiration Date: Tuesday, March 21, 2017
Time to Complete: 90 minutes
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity for any amount during the past 12 months.
Michele Spencer-Manzon, MD, FABMG
Assistant Professor of Genetics and Pediatrics
Yale School of Medicine
New Haven, Connecticut
Pierre Noel, MD
Blood and Marrow Transplant Program
Professor of Medicine
Kirk A. Tacka, PhD
PVI, PeerView Institute for Medical Education
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACMG will apply for Category 1 CEU approval for counselors through NSGC. Counselors may report attendance through the ACMG CE Self Reporting System. Symposia are not approved for P.A.C.E.® credit by ACMG. CME and P.A.C.E.® CEU credit will be available only if the sponsoring company has received ACCME and P.A.C.E.® accreditations.
This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.
This activity is supported by an educational grant from Sanofi Genzyme.
The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.
No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.
Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.